Research programme: anti-infectives - Ibis/SelectX

Drug Profile

Research programme: anti-infectives - Ibis/SelectX

Alternative Names: Anti-infectives research programme: Ibis/SelectX

Latest Information Update: 05 Oct 2004

Price : $50

At a glance

  • Originator Ibis Therapeutics; SelectX Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 05 Oct 2004 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 27 Aug 2004 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
  • 20 Sep 2002 OmniScience Pharmaceuticals has merged with BioChemist Inc. to form SelectX Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top